Ixazomib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Ixazomib. Educational only — not medical advice.
Labeled uses
NINLARO® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Source: FDA labeling via NIH DailyMed (set 038f2461…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.